Maxim Group Initiates Coverage On Innodata With Buy Rating, Announces Price Target of $30
Maxim Upgrades Synaptogenix to Buy From Hold, Price Target Is $14
Maxim Group Sticks to Its Buy Rating for Solaris Resources (SLSR)
Maxim Group Sticks to Its Hold Rating for Annovis Bio (ANVS)
Maxim Group Keeps Their Buy Rating on WISeKey International Holding (WKEY)
Maxim Adjusts Price Target on Apple to $195 From $178
Maxim Group Initiates Coverage On Virios Therapeutics With Buy Rating, Announces Price Target of $1
Maxim Group Keeps Their Hold Rating on SurgePays (SURG)
Maxim Group Downgrades Advanced Human Imaging (AHI) to a Hold
Maxim Group Remains a Hold on WiSA Technologies, Inc. (WISA)
Maxim Initiates GigaCloud Tech at Buy Rating With $69 Price Target
Maxim Group Remains a Buy on Reviva Pharmaceuticals Holdings (RVPH)
Maxim Group Sticks to Its Buy Rating for Acurx Pharmaceuticals (ACXP)
Maxim Group Downgrades Biolase (BIOL) to a Hold
Cutera (CUTR) Was Downgraded to a Hold Rating at Maxim Group
Maxim Group Reaffirms Their Buy Rating on Inuvo (INUV)
Maxim Adjusts Vivid Seats' Price Target to $9 From $7, Keeps Buy Rating
Maxim Adjusts Ryde Group's Price Target to $9 From $8, Keeps Buy Rating
Maxim Adjusts Paysign's Price Target to $6 From $5.50, Keeps Buy Rating
Maxim Adjusts Beyond's Price Target to $36 From $50, Keeps Buy Rating
No Data